Lung cancer screening: Current status and perspective

Abstract Lung cancer screening by low-dose computed tomography (CT) has been proven to reduce lung cancer-related mortality by 20%, in the National Lung cancer Screening Trial (NLST). Low-dose CT acquisition protocols should result in effective dose not exceeding 1.5 mSv, and should be read by radio...

Full description

Saved in:
Bibliographic Details
Published in:Diagnostic and interventional imaging 2016-10, Vol.97 (10), p.949-953
Main Authors: Chassagnon, G, Revel, M.-P
Format: Article
Language:English
Subjects:
Computed tomography
Cone-Beam Computed Tomography - methods
Early Detection of Cancer - methods
Early Detection of Cancer - trends
False Positive Reactions
Forecasting
Human health and pathology
Humans
Life Sciences
Lung
Lung cancer
Lung Neoplasms - diagnostic imaging
Lung Neoplasms - mortality
Lung Neoplasms - prevention & control
Pulmonology and respiratory tract
Radiation Dosage
Radiology
Screening
Sensitivity and Specificity
Tomography, X-Ray Computed - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Lung cancer screening by low-dose computed tomography (CT) has been proven to reduce lung cancer-related mortality by 20%, in the National Lung cancer Screening Trial (NLST). Low-dose CT acquisition protocols should result in effective dose not exceeding 1.5 mSv, and should be read by radiologists who have an expertise in the field. A volumetry-based approach similar to that used in the NELSON study allows reducing the rate of positive screens around 2%. The major harm of screening is overdiagnosis, which correspond to the detection of indolent tumours that would not cause the subject death. Ongoing research for the development of useful biomarkers to be combined to imaging could improve the accuracy of lung cancer screening.
ISSN:2211-5684
2211-5684
DOI:10.1016/j.diii.2016.06.018